The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating


High impact information on Polyradiculoneuropathy, Chronic Inflammatory Demyelinating


Chemical compound and disease context of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating


Biological context of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating


Anatomical context of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating


Gene context of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating


Analytical, diagnostic and therapeutic context of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating


  1. A 71-year-old male with 4 decades of symptoms referable to both central and peripheral nervous system. Quan, D., Kleinschmidt-DeMasters, B.K. Brain Pathol. (2005) [Pubmed]
  2. Low-titer antibodies reactive with HTLV-I gag p19 in patients with chronic myeloneuropathy. Kawanishi, T., Akiguchi, I., Fujita, M., Kameyama, M., Hatanaka, M. Ann. Neurol. (1989) [Pubmed]
  3. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Brannagan, T.H., Pradhan, A., Heiman-Patterson, T., Winkelman, A.C., Styler, M.J., Topolsky, D.L., Crilley, P.A., Schwartzman, R.J., Brodsky, I., Gladstone, D.E. Neurology (2002) [Pubmed]
  4. Electrodiagnostic features of hereditary neuropathy with liability to pressure palsies. Andersson, P.B., Yuen, E., Parko, K., So, Y.T. Neurology (2000) [Pubmed]
  5. Heterozygous P0 knockout mice develop a peripheral neuropathy that resembles chronic inflammatory demyelinating polyneuropathy (CIDP). Shy, M.E., Arroyo, E., Sladky, J., Menichella, D., Jiang, H., Xu, W., Kamholz, J., Scherer, S.S. J. Neuropathol. Exp. Neurol. (1997) [Pubmed]
  6. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Yan, W.X., Archelos, J.J., Hartung, H.P., Pollard, J.D. Ann. Neurol. (2001) [Pubmed]
  7. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Hughes, R., Bensa, S., Willison, H., Van den Bergh, P., Comi, G., Illa, I., Nobile-Orazio, E., van Doorn, P., Dalakas, M., Bojar, M., Swan, A. Ann. Neurol. (2001) [Pubmed]
  8. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Dyck, P.J., O'Brien, P.C., Oviatt, K.F., Dinapoli, R.P., Daube, J.R., Bartleson, J.D., Mokri, B., Swift, T., Low, P.A., Windebank, A.J. Ann. Neurol. (1982) [Pubmed]
  9. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Murata, K., Dalakas, M.C. Brain (2000) [Pubmed]
  10. Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Kolkin, S., Nahman, N.S., Mendell, J.R. Neurology (1987) [Pubmed]
  11. Pulse cyclophosphamide therapy in CIDP. Ikeda, K., Iwasaki, Y., Hatanaka, N., Kinoshita, M., Wakata, N. Neurology (1999) [Pubmed]
  12. Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy. Dyck, P.J., O'Brien, P., Swanson, C., Low, P., Daube, J. Neurology (1985) [Pubmed]
  13. Procainamide-induced chronic inflammatory demyelinating polyradiculoneuropathy. Erdem, S., Freimer, M.L., O'Dorisio, T., Mendell, J.R. Neurology (1998) [Pubmed]
  14. Distal acquired demyelinating symmetric neuropathy. Katz, J.S., Saperstein, D.S., Gronseth, G., Amato, A.A., Barohn, R.J. Neurology (2000) [Pubmed]
  15. Major histocompatibility complex class I and class II polymorphism in chronic idiopathic demyelinating polyradiculoneuropathy. Vaughan, R.W., Adam, A.M., Gray, I.A., Hughes, R.A., Sanders, E.A., van Dam, M., Welsh, K.I. J. Neuroimmunol. (1990) [Pubmed]
  16. Serum antibodies to GM1 and GM3-gangliosides in systemic lupus erythematosus with chronic inflammatory demyelinating polyradiculoneuropathy. Sindern, E., Stark, E., Haas, J., Steck, A.J. Acta neurologica Scandinavica. (1991) [Pubmed]
  17. Chronic inflammatory demyelinating polyneuropathy: histological and immunopathological studies on biopsied sural nerves. Matsumuro, K., Izumo, S., Umehara, F., Osame, M. J. Neurol. Sci. (1994) [Pubmed]
  18. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. Hughes, R.A., Allen, D., Makowska, A., Gregson, N.A. J. Peripher. Nerv. Syst. (2006) [Pubmed]
  19. Expression of accessory molecules for T-cell activation in peripheral nerve of patients with CIDP and vasculitic neuropathy. Van Rhijn, I., Van den Berg, L.H., Bosboom, W.M., Otten, H.G., Logtenberg, T. Brain (2000) [Pubmed]
  20. Anti-neuroblastoma cell line antibodies in inflammatory demyelinating polyneuropathy: inhibition in vitro and in vivo by IV immunoglobulin. van Doorn, P.A., Brand, A., Vermeulen, M. Neurology (1988) [Pubmed]
  21. Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy. Leppert, D., Hughes, P., Huber, S., Erne, B., Grygar, C., Said, G., Miller, K.M., Steck, A.J., Probst, A., Fuhr, P. Neurology (1999) [Pubmed]
  22. Expression of chemokines in cerebrospinal fluid and serum of patients with chronic inflammatory demyelinating polyneuropathy. Mahad, D.J., Howell, S.J., Woodroofe, M.N. J. Neurol. Neurosurg. Psychiatr. (2002) [Pubmed]
  23. Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. Kwa, M.S., van Schaik, I.N., Brand, A., Baas, F., Vermeulen, M. J. Neuroimmunol. (2001) [Pubmed]
  24. Aberrated levels of cerebrospinal fluid chemokines in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Press, R., Pashenkov, M., Jin, J.P., Link, H. J. Clin. Immunol. (2003) [Pubmed]
  25. Cystatin C and cathepsin B in CSF from patients with inflammatory neurologic diseases. Nagai, A., Murakawa, Y., Terashima, M., Shimode, K., Umegae, N., Takeuchi, H., Kobayashi, S. Neurology (2000) [Pubmed]
  26. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone. Lopate, G., Pestronk, A., Al-Lozi, M. Arch. Neurol. (2005) [Pubmed]
  27. Prednisone and plasma exchange improve suppressor cell function in chronic inflammatory demyelinating polyneuropathy. De Luca, G., Lugaresi, A., Iarlori, C., Marzoli, F., Di Iorio, A., Gambi, D., Uncini, A. J. Neuroimmunol. (1999) [Pubmed]
  28. Anti-SGPG antibody in CIDP: nosological position of IgM anti-MAG/SGPG antibody-associated neuropathy. Tagawa, Y., Yuki, N., Hirata, K. Muscle Nerve (2000) [Pubmed]
  29. Suggestive preliminary evidence from controlled 3-month clinical trials that prednisone improves chronic inflammatory polyradiculoneuropathy. Dyck, P.J., O'Brien, P.C., Oviatt, K.F., Bastron, J.A., Daube, J.R., Dinapoli, R.P., Groover, R.V., Stevens, J.C. Transactions of the American Neurological Association. (1978) [Pubmed]
WikiGenes - Universities